Biotechnology company · ONC

BeOne Medicines
clinical trial
pipeline

Registry checked

Published

Oncology is the largest mapped primary therapeutic group, with 57 of 68 active trials. This ranking covers mapped groups only. sonrotoclax is linked to 14 distinct active studies, with 2 Phase 1, 8 Phase 2, 4 Phase 3. Zanubrutinib is linked to 7 distinct active studies, with 5 Phase 3, 1 Phase 4, 1 without a recorded phase.

Phase 2 study NCT03736889 in MSI-H/dMMR Solid Tumors lists estimated primary completion in November 2026. Phase 2 study NCT04973605 in Relapsed/Refractory Multiple Myeloma lists estimated primary completion in November 2026. These are registry estimates of primary completion, not confirmed results announcements or overall study completion.

Active trial mix

Lead-sponsor scope

68active trials
as lead sponsor
  • Phase 129
  • Phase 217
  • Phase 319
  • Phase 41
  • Phase not recorded2

One highest explicitly recorded phase per active trial. Combined phases use the highest phase. Phase not recorded is shown separately.

Change history

Follow the changes behind the company’s clinical programme.

01 Oct 2026 – 30 Oct 2026 · UTC

Recorded changes

159 trials30 completed days
Recruitment statusPrimary completionEnrolmentFirst observedOther

Highlighted changes 03

Select an example to see what changed

01Primary completion

Primary completion moved later by 205 days

2027-12-31 (estimated)2028-07-23 (estimated)
31 Dec 202723 Jul 2028

A Study of BG-C477 in Participants With Advanced Solid Tumors

NCT06596473 · ClinicalTrials.gov
Recorded by ComplyRx
29 Oct 2026
Registry last updated
28 Oct 2026

Verified live registry-derived observations in completed UTC days. Recorded dates are observation dates, not necessarily registry amendment dates. Zero means no eligible observations recorded, not daily monitoring of every trial.

0 archive observations and 0 unverified observations excluded.

View exact daily values and type totals
Recorded observations in completed UTC days
Date (UTC)Recruitment statusPrimary completionEnrolmentFirst observedOtherTotalAffected trials
2026-10-010000000
2026-10-020000000
2026-10-030000000
2026-10-040000000
2026-10-050000000
2026-10-060100011
2026-10-070000000
2026-10-081000011
2026-10-090000000
2026-10-100100011
2026-10-110000000
2026-10-120000000
2026-10-130000000
2026-10-140000000
2026-10-150000000
2026-10-160000000
2026-10-170000000
2026-10-180000000
2026-10-190000000
2026-10-200310153
2026-10-210100121
2026-10-220000000
2026-10-231110031
2026-10-240000000
2026-10-250000000
2026-10-260000000
2026-10-270000000
2026-10-280000000
2026-10-290100121
2026-10-300000000
Type totals28203159 distinct

02 / Drugs & programmes

Explore the pipeline

6 selected programmes

Choose a drug to open its record in the tracker. Sign in to continue.

sonrotoclax

Canonical investigational asset

14
Active trials
6
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 12
  • Phase 28
  • Phase 34
  • Phase 40
  • Phase not recorded0
Studied condition
Acute Lymphoblastic Leukemia · Acute Myeloid Leukemia · B Cell Lymphoma
Next primary completion
Nov 2026 · estimated
Open drug

Zanubrutinib

brukinsa

7
Active trials
1
Recruiting trials
Trial phases
Highest: Phase 4
  • Phase 10
  • Phase 20
  • Phase 35
  • Phase 41
  • Phase not recorded1
Studied condition
B-cell Malignancies · Chronic Lymphocytic Leukemia · Mantle Cell Lymphoma; Non-Hodgkin Lymphoma
Next primary completion
31 December 2026 · estimated
Open drug

BGB-16673

Canonical investigational asset

7
Active trials
6
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 11
  • Phase 23
  • Phase 33
  • Phase 40
  • Phase not recorded0
Studied condition
B-cell Lymphoma · B-cell Malignancy · Chronic Lymphocytic Leukemia
Next primary completion
Mar 2027 · estimated
Open drug

Tislelizumab

tevimbra

6
Active trials
4
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 10
  • Phase 23
  • Phase 32
  • Phase 40
  • Phase not recorded1
Studied condition
Advanced Esophageal Squamous Cell Carcinoma · Advanced Gastroesophageal Adenocarcinoma · Advanced Non-Small Cell Lung Cancer
Next primary completion
Nov 2026 · estimated
Open drug

BGB-43395

Canonical investigational asset

3
Active trials
3
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 12
  • Phase 20
  • Phase 31
  • Phase 40
  • Phase not recorded0
Studied condition
Advanced Breast Cancer · Advanced Solid Tumor · Healthy Adult Participants
Next primary completion
Not reported
Open drug

Pamiparib

Canonical investigational asset

1
Active trials
0
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 10
  • Phase 20
  • Phase 31
  • Phase 40
  • Phase not recorded0
Studied condition
Ovarian Cancer
Next primary completion
Not reported
Open drug

41 of 68 active trials have accepted investigational programme links. Trial context does not establish ownership or complete drug coverage.

6 selected programmes · accepted investigational links cover 41 of 68 active trials · brand names checked where available.

Accepted links do not establish complete intervention mapping or ownership. Programme populations overlap.

Up to six canonical assets identified through accepted investigational links in active trials. Counts describe this trial context and do not establish ownership or a complete corporate drug portfolio. Opening a record requires sign-in and does not start tracking.

03 / Clinical trial timeline

BeOne Medicines trials in progress

Registry start → study completion

◇ Recorded observation│ Primary completion milestoneHatched ends retain month / year uncertaintyHover, focus or tap an observation
Trial / programme
6 selected Phase 3 / 2 trials
2021202220232024202520262027202820292030
Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors
Tislelizumab

NCT03736889

Phase 2 · Recruiting

Trial source and qualifications

Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors

Duration ends at independently recorded study completion. Source date qualifications: start-clipped-at-horizon. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history.

Start clipped at the display horizon.

0 candidate observations · 0 shown · 0 recorded after primary completion · 0 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

ClinicalTrials.gov source

No eligible observations recorded in the inspected period.

    Start: 19 Sept 2018 · actual
    Primary completion: Nov 2026 · estimated
    Study completion: Sept 2027 · estimated

    2021202220232024202520262027202820292030
    A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
    sonrotoclax

    NCT04973605

    Phase 2 · Recruiting

    Trial source and qualifications

    A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

    Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 1 inspected observations were not displayed.

    1 candidate observations · 0 shown · 0 recorded after primary completion · 1 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

    ClinicalTrials.gov source

    1 inspected observations omitted. At most three verified observations are shown, not full history.

      Start: 16 Sept 2021 · actual
      Primary completion: Nov 2026 · estimated
      Study completion: Nov 2026 · estimated

      2021202220232024202520262027202820292030
      A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia
      sonrotoclax

      NCT06637501

      Phase 2 · Active, not recruiting

      Trial source and qualifications

      A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia

      Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 2 inspected observations were not displayed.

      2 candidate observations · 0 shown · 0 recorded after primary completion · 2 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

      ClinicalTrials.gov source

      2 inspected observations omitted. At most three verified observations are shown, not full history.

        Start: 14 Nov 2024 · actual
        Primary completion: Nov 2026 · estimated
        Study completion: Sept 2029 · estimated

        2021202220232024202520262027202820292030
        A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib
        Zanubrutinib

        NCT04170283

        Phase 3 · Active, not recruiting

        Trial source and qualifications

        A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib

        Duration ends at independently recorded study completion. Source date qualifications: start-clipped-at-horizon. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 2 inspected observations were not displayed.

        Start clipped at the display horizon.

        2 candidate observations · 0 shown · 0 recorded after primary completion · 2 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

        ClinicalTrials.gov source

        2 inspected observations omitted. At most three verified observations are shown, not full history.

          Start: 16 Jan 2020 · actual
          Primary completion: 31 Dec 2026 · estimated
          Study completion: 31 Dec 2026 · estimated

          2021202220232024202520262027202820292030
          CaDAnCe-101
          BGB-16673

          NCT05006716

          Phase 2 · Recruiting

          Trial source and qualifications

          A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

          Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 3 inspected observations were not displayed.

          4 candidate observations · 1 shown · 0 recorded after primary completion · 3 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

          ClinicalTrials.gov source

          3 inspected observations omitted. At most three verified observations are shown, not full history.

          • pc date moved · Recorded 2026-10-06 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.

          Start: 13 Sept 2021 · actual
          Primary completion: Mar 2027 · estimated
          Study completion: Mar 2030 · estimated

          2021202220232024202520262027202820292030
          A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
          Asset mapping not recorded

          NCT06427941

          Phase 2 · Recruiting

          Trial source and qualifications

          A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors

          Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 2 inspected observations were not displayed.

          4 candidate observations · 2 shown · 0 recorded after primary completion · 2 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

          ClinicalTrials.gov source

          2 inspected observations omitted. At most three verified observations are shown, not full history.

          • pc date moved · Recorded 2026-09-08 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.
          • enrollment change · Recorded 2026-09-08 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.

          Start: 23 Jul 2024 · actual
          Primary completion: 31 Mar 2027 · estimated
          Study completion: 31 Oct 2028 · estimated

          2021202220232024202520262027202820292030

          Up to six active Phase 2/3 trials with upcoming estimated primary-completion intervals, ordered by nearest interval, highest phase and NCT. Historical dates never pad this selection. Ten calendar years are shown. Dates retain registry precision and independent date types.

          6 selected of 24 eligible trials · 0 without supported dates · 0 omitted for contradictory chronology. Excluded: 9 actual primary completions, 0 untyped primary completions, 0 past estimates, 3 outside the horizon, 0 contradictory dates.

          04 / Therapeutic focus

          Where the activity is

          57

          active trials in Oncology

          Primary therapeutic groups are indexed enrichment. Unmapped trials and healthy volunteers remain in the active-trial denominator.

          Active trials by primary therapeutic area

          • Oncology57 trials
          • Dermatology2 trials
          • Gastroenterology & Hepatology2 trials
          • Renal & Urology1 trials
          • Unmapped3 trials
          • Healthy volunteers3 trials

          Each active trial counts once. Full bar equals all active trials in this lead-sponsor scope. This grouping does not describe commercial strategy.

          06 / Related companies

          All companies

          Based on the selected programmes and indexed lead-sponsor records, not a complete ranking or a competitive/ownership assessment.

          Sources, scope and methodology

          ClinicalTrials.gov lead-sponsor scope

          Canonical current-owner attribution covers 192 distinct NCT records attributed through the canonical sponsor map. Included canonical entities: BeiGene. Phrases retrieve candidates only, then verbatim lead-sponsor attribution determines inclusion.

          ClinicalTrials.gov

          Attribution coverage

          193 distinct registry candidates produced 192 accepted studies. 0 mapped to other owners, 1 lacked a canonical mapping and 0 fell outside an operating subset. Accepted mappings include 192 unverified, 67 identity-only and 0 device-tagged trial memberships. Mapping flags describe evidence quality, not a separate ownership authority.

          Indexed enrichment

          192 scoped records have indexed enrichment and 0 do not. Missing enrichment does not remove a trial from cohort counts.

          Scope observation

          The successful attribution check completed at 2026-10-31T23:01:23.258Z. This is a dated canonical-attribution snapshot. Static pages normally regenerate after 24 hours, but cached HTML can outlive that interval when regeneration fails. Map changes affect the next successful regeneration. This timestamp is separate from individual registry-update dates. Snapshot 71ddeb2f443f61f5dbc7a415ba9c5f9c51ba42cea8b72c3526c206aab53a7b5b.

          Active means recruiting, not yet recruiting, active not recruiting or enrolling by invitation. Recruiting counts recruiting only. Trial counts describe lead sponsorship under the published canonical-attribution policy. Identified programmes and therapeutic groups depend on available enrichment. Drug, device and other clinical studies may be included. This is the mapped company scope, not an exhaustive corporate trial census.

          Dated canonical-attribution snapshot: 192 mapped lead-sponsored clinical studies across all statuses. 192 have indexed enrichment. Drug, device and other studies may be represented. Sponsor tags do not classify trial interventions. This is the mapped company scope, not an exhaustive corporate trial census. Recorded changes may reflect observation or archive ingestion rather than a new registry amendment.

          Keep following
          what matters.

          Choose the drugs, companies or disease areas you follow. Bring trial changes and upcoming readouts into one watch.

          Build your watch

          Choose what to track in the watch builder.